Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study

J Crit Care. 2020 Dec:60:328-333. doi: 10.1016/j.jcrc.2020.07.001. Epub 2020 Jul 31.

Abstract

Purpose: We investigated the effect of therapeutic plasma exchange (TPE) on life-threatening COVID-19; presenting as acute respiratory distress syndrome (ARDS) plus multi-system organ failure and cytokine release syndrome (CRS).

Materials and methods: We prospectively enrolled ten consecutive adult intensive care unit (ICU) subjects [7 males; median age: 51 interquartile range (IQR): 45.1-55.9 years old] with life-threatening COVID-19 infection. All had ARDS [PaO2/FiO2 ratio: 110 (IQR): 95.5-135.5], septic shock, CRS and deteriorated within 24 h of ICU admission despite fluid resuscitation, antibiotics, hydroxychloroquine, ARDS-net and prone position mechanical ventilation. All received 5-7 TPE sessions (dosed as 1.0 to 1.5 plasma volumes).

Results: All of the following significantly normalized (p < 0.05) following the TPE completion, when compared to baseline: Sequential Organ Function Assessment score, PaO2/FiO2 ratio, levels of lymphocytes, total bilirubin, lactate dehydrogenase, ferritin, C-reactive protein and interleukin-6. No adverse effects from TPE were observed. Acute kidney injury and pulmonary embolism were observed in 10% and 20% of patients, respectively. The duration of mechanical ventilation was 9 (IQR: 7 to 12) days, the ICU length of stay was 15 (IQR: 13.2 to 19.6) days and the mortality on day-28 was 10%.

Conclusion: TPE demonstrates a potential survival benefit and low risk in life-threatening COVID-19, albeit in a small pilot study.

Keywords: Acute respiratory distress syndrome; Cytokine release syndrome; Intensive care unit; Life-threatening COVID-19; Therapeutic plasma exchange.

MeSH terms

  • Adult
  • Aged
  • Bilirubin / blood
  • C-Reactive Protein / analysis
  • COVID-19 / complications
  • COVID-19 / therapy*
  • Critical Care
  • Critical Illness / therapy*
  • Female
  • Ferritins / blood
  • Humans
  • Intensive Care Units
  • Interleukin-6 / blood
  • L-Lactate Dehydrogenase / blood
  • Male
  • Middle Aged
  • Multiple Organ Failure / therapy
  • Patient Positioning
  • Pilot Projects
  • Plasma Exchange / methods*
  • Prone Position
  • Prospective Studies
  • Respiration, Artificial
  • Respiratory Distress Syndrome / complications
  • Respiratory Distress Syndrome / therapy*
  • Treatment Outcome

Substances

  • IL6 protein, human
  • Interleukin-6
  • C-Reactive Protein
  • Ferritins
  • L-Lactate Dehydrogenase
  • Bilirubin